GlassScriptPhysician profile
Jayson Gesulga
NPI 1972989721
$877,776.80
in general payments reported to CMS, 2019-2025
26 companies · $300K in 2025
The $300K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31K · 2022: $122K · 2023: $167K · 2024: $259K · 2025: $300K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $525K · Travel and Lodging: $139K · Consulting Fee: $36K · Food and Beverage: $24K · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $525,312.25 |
| Travel and Lodging | $138,993.54 |
| Consulting Fee | $36,280.50 |
| Food and Beverage | $24,088.49 |
| Education | $276.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $338,848.94 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212,160.90 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $107,277.60 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $88,036.00 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $54,464.98 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $34,355.09 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $31,194.20 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Idorsia Pharmaceuticals US INC | $6,149.08 | 2022-2023 | Quviviq |
| Neuronetics, INC. | $1,687.16 | 2024 | Neurostar Tms Therapy System |
| Allergan, INC. | $825.00 | 2021 | |
| Axsome Therapeutics, INC. | $606.69 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $527.77 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $317.25 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $295.31 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.00 | 2021-2025 | Trintellix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $169.75 | 2022-2024 | Fanapt, Hetlioz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $150.96 | 2022-2025 | Abilify Asimtufii, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.30 | 2024 | |
| Novo Nordisk INC | $60.40 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Indivior INC. | $59.83 | 2022-2023 | Perseris |
| Celgene Corporation | $56.38 | 2024 | |
| Almatica Pharma LLC | $54.44 | 2021-2024 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $42.53 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $21.90 | 2024 | Qelbree |
| Noven Therapeutics, LLC | $17.97 | 2025 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $17.37 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayson Gesulga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.